1 / 2

The Antibody Service and more Efficient Processes

Boston Molecules contain Antibody services and Base editing which is growing at compound annual rate since 2014 contain biopharmaceutical products which become more dynamic and rapidly expanding in market.

bostonmol
Download Presentation

The Antibody Service and more Efficient Processes

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Antibody Service and more Efficient Processes The global biopharmaceutical Antibody Service in market is growing at a compound annual rate of 10% since 2014 and is expected to reach approximately $390 billion by the end of 2019). Therapeutic monoclonal antibodies (mAb) are a key class of biopharmaceutical products that has grown briskly in product approvals and sales, from the time when the first mAb was commercialized. As shown in Figure a, Humira®, an antitumor necrosis factor-α mAb manufactured by AbbVie (AbbVie Inc., North Chicago, IL), achieved gross sales of $12.5 billion in 2014and increased by 28.8% in 2016 to reach $16 billion. The biopharmaceutical Antibody Service in market has become more dynamic with the recent increase in the entry of biopharma companies into the biosimilars business. To maintain a competitive space in such a rapidly expanding market, in the next 5 years, the top 20 biopharma companies are expected to invest $109 billion in research and development (R&D; Figure b,c) and the overall R&D expenditure is expected to increase 2.8% each year to

  2. reach $182 billion by 2022. From a process development perspective, most of the R&D is focused on intensifying and integrating bioprocess technologies to increase efficiency and flexibility in biopharmaceutical manufacturing. Base Editing is faster and more efficient processes, continuous manufacturing, designed to enhance efficiency, has emerged as a new modality in biomanufacturing. This study elaborates on the current trends and potential risks in continuous downstream processing of mAbs with a primary focus on continuous chromatography. We provide insights into the ways to move from bench-scale solutions to industrial implementation. Furthermore, the article highlights the importance of a holistic approach to process development and characterization to address the regulatory challenges related to introducing continuous downstream processing at manufacturing scale. Contact Information Boston Molecules Inc. 564 Main Street, Waltham, MA 02452, USA Website: www.bostonmolecules.com Phone: 617-651-1016 Email: info@bostonmolecules.com

More Related